Table 3.
Representative enriched KEGG pathways, involved in heart function or disease, according to in silico analysis of predicted targets of miRNAs associated with clinical parameters in failing heart with/without LVAD support.
| KEGG pathway | P value | Number of miRNAs | Number of target genes (% in the pathway) |
|---|---|---|---|
| Regulation of actin cytoskeleton | 1.44E − 04 | 9 | 29 (13.5%) |
| Focal adhesion | 1.37E − 16 | 8 | 40 (19.3%) |
| PI3K-Akt signaling pathway | 1.15E − 11 | 8 | 50 (14.4%) |
| mTOR signaling pathway | 9.89E − 06 | 8 | 13 (21.7%) |
| Dilated cardiomyopathy | 5.46E − 05 | 8 | 15 (16.7%) |
| Wnt signaling pathway | 6.04E − 05 | 8 | 20 (14.4%) |
| Hypertrophic cardiomyopathy (HCM) | 7.65E − 05 | 8 | 14 (16.9%) |
| Arrhythmogenic right ventricular cardiomyopathy | 1.77E − 03 | 8 | 13 (17.6%) |
| ECM-receptor interaction | 3.21E − 53 | 7 | 23 (26.4%) |
| MAPK signaling pathway | 1.39E − 06 | 7 | 36 (14.0%) |
| Cytokine-cytokine receptor interaction | 5.73E − 03 | 7 | 24 (9.1%) |
| TGF-beta signaling pathway | 9.21E − 06 | 6 | 16 (20.0%) |
| Adherens junction | 4.53E − 04 | 6 | 11 (15.1%) |
| Phosphatidylinositol signaling system | 3.51E − 03 | 5 | 12 (14.8%) |